Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic

M. Kasperkiewicz; E. Schmidt; M. Amagai; J. A. Fairley; P. Joly; D. F. Murrell; A. S. Payne; M. L. Yale; D. Zillikens; D. T. Woodley

doi:10.1111/jdv.17207

Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic

M. Kasperkiewicz^*, E. Schmidt, M. Amagai, J. A. Fairley, P. Joly, D. F. Murrell, A. S. Payne, M. L. Yale, D. Zillikens, D. T. Woodley

^*Korrespondierende/r Autor/-in für diese Arbeit

32 Zitate (Scopus)

Originalsprache	Englisch
Zeitschrift	Journal of the European Academy of Dermatology and Venereology
Jahrgang	35
Ausgabenummer	7
Seiten (von - bis)	e412-e414
Seitenumfang	3
ISSN	0926-9959
DOIs	https://doi.org/10.1111/jdv.17207
Publikationsstatus	Veröffentlicht - 07.2021

Fördermittel

Dr. Schmidt reports grants and personal fees from UCB, grants and personal fees from Biotest, grants from Incyte, grants from Euroimmun, personal fees from Novartis, grants and personal fees from ArgenX, personal fees from Astra Zeneca, grants and personal fees from Fresenius Medical Care, grants from Dompe, grants from Synthon, grants from Admirx and personal fees from Thermo Fisher, outside the submitted work; Dr. Amagai reports grants from Ono Pharmaceutical Company, grants from MBL and grants from RegCell, outside the submitted work; Dr. Fairley reports grants from National Institutes of Health and other from AstraZeneca, outside the submitted work; Dr. Murrell has served as a Principal Investigator and Advisor for trials with Principia Biopharma, Roche and Sanofi; Dr. Payne reports grants, personal fees and non‐financial support from Cabaletta Bio and personal fees from Villaris Therapeutics, outside the submitted work; in addition, Dr. Payne has a patent Compositions and methods of chimeric autoantibody receptor T cells with royalties paid from Cabaletta Bio, a patent Compositions and methods for selective protein expression with royalties paid from Novartis, and a patent Method of redirecting T cells to treat HIV infection with royalties paid from Tmunity; Dr. Zillikens reports personal fees from UCB, Almirall, ArGEN‐x, grants from Biotest, Euroimmun, Fresenius, personal fees from Biotest, Fresenius, Miltenyi, Roche, Biogen, Abbvie, UCB, Janssen, Novartis, outside the submitted work; Mr. Yale and Drs. Kasperkiewicz, Joly and Woodley have nothing to disclose.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)

Coronavirus-Bezug

Forschung zu SARS-CoV-2 / COVID-19

Dokumente

10.1111/jdv.17207

Weitere Links

Zitieren

Kasperkiewicz, M., Schmidt, E., Amagai, M., Fairley, J. A., Joly, P., Murrell, D. F., Payne, A. S., Yale, M. L., Zillikens, D., & Woodley, D. T. (2021). Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic. Journal of the European Academy of Dermatology and Venereology, 35(7), e412-e414. https://doi.org/10.1111/jdv.17207

@article{b395b73039ff4ab3b4f3ecaa27f66268,

title = "Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic",

author = "M. Kasperkiewicz and E. Schmidt and M. Amagai and Fairley, \{J. A.\} and P. Joly and Murrell, \{D. F.\} and Payne, \{A. S.\} and Yale, \{M. L.\} and D. Zillikens and Woodley, \{D. T.\}",

note = "Funding Information: Dr. Schmidt reports grants and personal fees from UCB, grants and personal fees from Biotest, grants from Incyte, grants from Euroimmun, personal fees from Novartis, grants and personal fees from ArgenX, personal fees from Astra Zeneca, grants and personal fees from Fresenius Medical Care, grants from Dompe, grants from Synthon, grants from Admirx and personal fees from Thermo Fisher, outside the submitted work; Dr. Amagai reports grants from Ono Pharmaceutical Company, grants from MBL and grants from RegCell, outside the submitted work; Dr. Fairley reports grants from National Institutes of Health and other from AstraZeneca, outside the submitted work; Dr. Murrell has served as a Principal Investigator and Advisor for trials with Principia Biopharma, Roche and Sanofi; Dr. Payne reports grants, personal fees and non‐financial support from Cabaletta Bio and personal fees from Villaris Therapeutics, outside the submitted work; in addition, Dr. Payne has a patent Compositions and methods of chimeric autoantibody receptor T cells with royalties paid from Cabaletta Bio, a patent Compositions and methods for selective protein expression with royalties paid from Novartis, and a patent Method of redirecting T cells to treat HIV infection with royalties paid from Tmunity; Dr. Zillikens reports personal fees from UCB, Almirall, ArGEN‐x, grants from Biotest, Euroimmun, Fresenius, personal fees from Biotest, Fresenius, Miltenyi, Roche, Biogen, Abbvie, UCB, Janssen, Novartis, outside the submitted work; Mr. Yale and Drs. Kasperkiewicz, Joly and Woodley have nothing to disclose.",

year = "2021",

month = jul,

doi = "10.1111/jdv.17207",

language = "English",

volume = "35",

pages = "e412--e414",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "John Wiley and Sons Inc",

number = "7",

}

Kasperkiewicz, M, Schmidt, E, Amagai, M, Fairley, JA, Joly, P, Murrell, DF, Payne, AS, Yale, ML, Zillikens, D & Woodley, DT 2021, 'Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic', Journal of the European Academy of Dermatology and Venereology, Jg. 35, Nr. 7, S. e412-e414. https://doi.org/10.1111/jdv.17207

TY - JOUR

T1 - Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic

AU - Kasperkiewicz, M.

AU - Schmidt, E.

AU - Amagai, M.

AU - Fairley, J. A.

AU - Joly, P.

AU - Murrell, D. F.

AU - Payne, A. S.

AU - Yale, M. L.

AU - Zillikens, D.

AU - Woodley, D. T.

N1 - Funding Information: Dr. Schmidt reports grants and personal fees from UCB, grants and personal fees from Biotest, grants from Incyte, grants from Euroimmun, personal fees from Novartis, grants and personal fees from ArgenX, personal fees from Astra Zeneca, grants and personal fees from Fresenius Medical Care, grants from Dompe, grants from Synthon, grants from Admirx and personal fees from Thermo Fisher, outside the submitted work; Dr. Amagai reports grants from Ono Pharmaceutical Company, grants from MBL and grants from RegCell, outside the submitted work; Dr. Fairley reports grants from National Institutes of Health and other from AstraZeneca, outside the submitted work; Dr. Murrell has served as a Principal Investigator and Advisor for trials with Principia Biopharma, Roche and Sanofi; Dr. Payne reports grants, personal fees and non‐financial support from Cabaletta Bio and personal fees from Villaris Therapeutics, outside the submitted work; in addition, Dr. Payne has a patent Compositions and methods of chimeric autoantibody receptor T cells with royalties paid from Cabaletta Bio, a patent Compositions and methods for selective protein expression with royalties paid from Novartis, and a patent Method of redirecting T cells to treat HIV infection with royalties paid from Tmunity; Dr. Zillikens reports personal fees from UCB, Almirall, ArGEN‐x, grants from Biotest, Euroimmun, Fresenius, personal fees from Biotest, Fresenius, Miltenyi, Roche, Biogen, Abbvie, UCB, Janssen, Novartis, outside the submitted work; Mr. Yale and Drs. Kasperkiewicz, Joly and Woodley have nothing to disclose.

PY - 2021/7

Y1 - 2021/7

UR - https://www.scopus.com/pages/publications/85102745053

UR - https://www.mendeley.com/catalogue/8a608694-43f1-3e9d-ac66-1ccc9960cf60/

U2 - 10.1111/jdv.17207

DO - 10.1111/jdv.17207

M3 - Letters

C2 - 33655539

AN - SCOPUS:85102745053

SN - 0926-9959

VL - 35

SP - e412-e414

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 7

ER -